循环游离DNA分析揭示与PARP抑制剂耐药相关的BRCA2回复突变的多克隆异质性
约20%的转移性前列腺癌存在同源重组修复(HRR)基因突变,BRCA2缺陷对奥拉帕利和他拉唑帕利等PARP抑制剂(PARPi)合成致死。在卵巢癌或乳腺癌中,奥拉帕利耐药与HRR恢复(包括BRCA2突变回复)相关;该机制是否在前列腺癌中起作用并可经液体活检检测尚不清楚。本研究在前列腺癌患者中鉴定出与奥拉帕利和他拉唑帕利耐药相关的BRCA2回复突变,循环游离DNA(cfDNA)分析揭示单次实体瘤活检无法辨别的回复突变异质性,并可能监测PARPi耐药的出现。
要点
- 前列腺癌患者中鉴定出与奥拉帕利和他拉唑帕利耐药相关的BRCA2回复突变。
- cfDNA分析揭示单次实体瘤活检无法辨别的回复突变异质性。
- cfDNA可能用于监测PARPi耐药的出现。
核心结论
- 在前列腺癌患者中鉴定出与奥拉帕利和他拉唑帕利耐药相关的BRCA2回复突变。
- PARPi耐药高度多克隆,cfDNA可监测PARPi耐药。
研究设计与样本
- 对前列腺癌患者的循环游离DNA(cfDNA)进行分析。
主要发现
- 在前列腺癌患者中鉴定出与奥拉帕利和他拉唑帕利耐药相关的BRCA2回复突变。
- cfDNA分析揭示单次实体瘤活检无法辨别的回复突变异质性。
- cfDNA可能监测PARPi耐药的出现。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approximately 20% of metastatic prostate cancers harbor mutations in genes required for DNA repair by homologous recombination repair (HRR) such as BRCA2 HRR defects confer synthetic lethality to PARP inhibitors (PARPi) such as olaparib and talazoparib. In ovarian or breast cancers, olaparib resistance has been associated with HRR restoration, including by BRCA2 mutation reversion. Whether similar mechanisms operate in prostate cancer, and could be detected in liquid biopsies, is unclear. Here, we identify BRCA2 reversion mutations associated with olaparib and talazoparib resistance in patients with prostate cancer. Analysis of circulating cell-free DNA (cfDNA) reveals reversion mutation heterogeneity not discernable from a single solid-tumor biopsy and potentially allows monitoring for the emergence of PARPi resistance.Significance: The mechanisms of clinical resistance to PARPi in DNA repair-deficient prostate cancer have not been described. Here, we show BRCA2 reversion mutations in patients with prostate cancer with metastatic disease who developed resistance to talazoparib and olaparib. Furthermore, we show that PARPi resistance is highly multiclonal and that cfDNA allows monitoring for PARPi resistance. Cancer Discov; 7(9); 999-1005. ©2017 AACR.See related commentary by Domchek, p. 937See related article by Kondrashova et al., p. 984See related article by Goodall et al., p. 1006This article is highlighted in the In This Issue feature, p. 920.
引用
- Quigley D, Alumkal JJ, Wyatt AW, et al. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017. PMID: 28450426. doi:10.1158/2159-8290.CD-17-0146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。